CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist

CureGene said the first subject has been dosed in its Phase I trial of CG-0416, a novel oral liver-targeting THR-β agonist, in Australia. The company stated subject enrollment is progressing smoothly, with the program continuing as planned. Overall, this is an early-stage positive clinical development likely to be modest near-term for investors.

Analysis

CureGene said the first subject has been dosed in its Phase I trial of CG-0416, a novel oral liver-targeting THR-β agonist, in Australia. The company stated subject enrollment is progressing smoothly, with the program continuing as planned. Overall, this is an early-stage positive clinical development likely to be modest near-term for investors.